Journal: bioRxiv

Article Title: Bcl-xL as a poor prognostic biomarker and predictor of response to adjuvant chemotherapy specifically in BRAF -mutant stage II and III colon cancer

doi: 10.1101/207639

Figure Lengend Snippet: A. BCL2L1 ( Bcl-xL ) was represented by 3 individual probesets in relapse risk analysis in BRAFMT tumors. B + C. Relapse-free survival (RFS) curve using Kaplan-Meier estimation in the “Initial Consolidation” dataset comparing tertile stratified Bcl-xL gene expression levels in all BRAFMT (A) and untreated BRAFMT (B) stage II/III CRC patients. Unadjusted and adjusted HR statistics are detailed in Table 3.

Article Snippet: Analysis of matched Bcl-xL transcript abundance (by Agilent microarray) and protein levels (by Reverse Phase Protein Array (RPPA)) from 102 CRC tumor samples within The Cancer Genome Atlas (TCGA)[ ] indicated a significant correlation between both methodologies (p=0.001; Supplementary Figure 5B), supporting protein-based assessment as an appropriate methodology to validate our data in an independent cohort.

Techniques: Expressing

Journal: bioRxiv

Article Title: Bcl-xL as a poor prognostic biomarker and predictor of response to adjuvant chemotherapy specifically in BRAF -mutant stage II and III colon cancer

doi: 10.1101/207639

Figure Lengend Snippet: A. Whole-face CC tissue sections were used to optimize IHC protocol. A low level of protein expression was observed in the normal glands compared to surrounding stroma (Blue box) Elevated levels of expression were observed in neoplastic glands compared to both the normal glands and surrounding stroma (Red box). Some staining in the stroma is evident in both normal and cancer-associated regions. B. Representative images of high, medium and low Bcl-xL protein expression by IHC in an independent “Northern Ireland cohort” of stage II/III CRC (Northern Ireland cohort; n=740).

Article Snippet: Analysis of matched Bcl-xL transcript abundance (by Agilent microarray) and protein levels (by Reverse Phase Protein Array (RPPA)) from 102 CRC tumor samples within The Cancer Genome Atlas (TCGA)[ ] indicated a significant correlation between both methodologies (p=0.001; Supplementary Figure 5B), supporting protein-based assessment as an appropriate methodology to validate our data in an independent cohort.

Techniques: Expressing, Staining, Northern Blot

Journal: bioRxiv

Article Title: Bcl-xL as a poor prognostic biomarker and predictor of response to adjuvant chemotherapy specifically in BRAF -mutant stage II and III colon cancer

doi: 10.1101/207639

Figure Lengend Snippet: A. Colorectal cancer disease-specific survival (DSS) curve using Kaplan-Meier estimation in the “Northern Ireland cohort” comparing tertiles stratification of Bcl-xL protein expression (by IHC H-score) in untreated BRAFMT stage II/III CC patients. B. DSS of patients in the highest tertile of Bcl-xL protein expression stratified according to adjuvant chemotherapy treatment received. C. DSS of patients in the lowest tertile of Bcl-xL protein expression stratified according to adjuvant chemotherapy treatment received. Unadjusted and adjusted HR statistics are detailed in Table 4.

Article Snippet: Analysis of matched Bcl-xL transcript abundance (by Agilent microarray) and protein levels (by Reverse Phase Protein Array (RPPA)) from 102 CRC tumor samples within The Cancer Genome Atlas (TCGA)[ ] indicated a significant correlation between both methodologies (p=0.001; Supplementary Figure 5B), supporting protein-based assessment as an appropriate methodology to validate our data in an independent cohort.

Techniques: Northern Blot, Expressing